Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Chapman

Showing results (801-810 of 1,011) with videos related to

Pageof 102
Sort By:
The New England Journal of Medicine|November 9, 2012
Progression of RAS-mutant leukemia during RAF inhibitor treatmentMargaret K Callahan, Raajit Rampal, James J Harding, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
Melanoma Research|January 23, 2016
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanomaAlexander N Shoushtari, Leonard T Ong, Heiko Schoder, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 29, 2005
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)W Charles O'Neill, Michelle L Robbin, Kyongtae T Bae, et al.
Kidney International|April 2, 2015
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney diseaseHarpreet Bhutani, Vikram Smith, Frederic Rahbari-Oskoui, et al.
Cancer|April 30, 2005
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II studyWen-Jen Hwu, Eric Lis, Jennifer H Menell, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.
American Journal of Nephrology|March 1, 2014
Novel methodology to evaluate renal cysts in polycystic kidney diseaseKyongtae T Bae, Hongliang Sun, June Goo Lee, et al.
Metabolic Syndrome and Related Disorders|February 10, 2015
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patientsLiming Weng, Eoin Quinlivan, Yan Gong, et al.
Annals of Surgical Oncology|December 19, 2019
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint BlockadeDanielle M Bello, Katherine S Panageas, Travis Hollmann, et al.
Pageof 102

Showing results (801-810 of 1,011) with videos related to

Sort By:
Pageof 102
The New England Journal of Medicine|November 9, 2012
Progression of RAS-mutant leukemia during RAF inhibitor treatmentMargaret K Callahan, Raajit Rampal, James J Harding, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
Melanoma Research|January 23, 2016
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanomaAlexander N Shoushtari, Leonard T Ong, Heiko Schoder, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 29, 2005
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP)W Charles O'Neill, Michelle L Robbin, Kyongtae T Bae, et al.
Kidney International|April 2, 2015
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney diseaseHarpreet Bhutani, Vikram Smith, Frederic Rahbari-Oskoui, et al.
Cancer|April 30, 2005
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II studyWen-Jen Hwu, Eric Lis, Jennifer H Menell, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 21, 2005
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901John D Roberts, Donna Niedzwiecki, William E Carson, et al.
American Journal of Nephrology|March 1, 2014
Novel methodology to evaluate renal cysts in polycystic kidney diseaseKyongtae T Bae, Hongliang Sun, June Goo Lee, et al.
Metabolic Syndrome and Related Disorders|February 10, 2015
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patientsLiming Weng, Eoin Quinlivan, Yan Gong, et al.
Annals of Surgical Oncology|December 19, 2019
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint BlockadeDanielle M Bello, Katherine S Panageas, Travis Hollmann, et al.
Pageof 102